Bio Green Med Solution (BGMS)
Market Price (10/5/2026): $0.9198 | Market Cap: $5.1 MilSector: Industrials | Industry: Building Products
Bio Green Med Solution (BGMS)
Market Price (10/5/2026): $0.9198Market Cap: $5.1 MilSector: IndustrialsIndustry: Building Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -77% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18510% Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -164% | Penny stockMkt Price is 0.9 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -147% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 36% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -59%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -59% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% High stock price volatilityVol 12M is 122% Key risksBGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -77% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 18510% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -164% |
| Penny stockMkt Price is 0.9 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -147% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 36% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -59%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -59% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -50% |
| High stock price volatilityVol 12M is 122% |
| Key risksBGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bio Green Med Solution (BGMS) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Significant Shareholder Dilution from Future NRG Acquisition.
The business combination agreement to acquire Future NRG Sdn. Bhd., announced in June 2026, stipulated that Future NRG shareholders are expected to own more than 99% of the combined company upon the deal's closing in fiscal Q4 2026. This significant equity transfer implies substantial dilution for existing Bio Green Med Solution shareholders, which likely weighed on the stock despite an initial positive market reaction to the acquisition announcement.
2. Shareholder Litigation Concerns.
Beginning in July and continuing into September 2026, several class action firms launched investigations into whether the proposed transactions, specifically the Future NRG merger, were structured fairly for Bio Green Med Solution shareholders. These investigations introduce legal uncertainty and suggest potential challenges to the terms of the deal, contributing to negative sentiment and pressure on the stock price.
Show more
Bio Green Med Solution (BGMS) stock has lost about 5% since 6/30/2026 because of the following key factors:
1. Significant Shareholder Dilution from Future NRG Acquisition.
The business combination agreement to acquire Future NRG Sdn. Bhd., announced in June 2026, stipulated that Future NRG shareholders are expected to own more than 99% of the combined company upon the deal's closing in fiscal Q4 2026. This significant equity transfer implies substantial dilution for existing Bio Green Med Solution shareholders, which likely weighed on the stock despite an initial positive market reaction to the acquisition announcement.
2. Shareholder Litigation Concerns.
Beginning in July and continuing into September 2026, several class action firms launched investigations into whether the proposed transactions, specifically the Future NRG merger, were structured fairly for Bio Green Med Solution shareholders. These investigations introduce legal uncertainty and suggest potential challenges to the terms of the deal, contributing to negative sentiment and pressure on the stock price.
3. Limited Cash Runway.
In its fiscal Q2 2026 financial results, reported on August 12, 2026, Bio Green Med Solution indicated cash and cash equivalents of $3.8 million as of June 30, 2026. The company estimated that these resources would only fund planned expenditures into fiscal Q1 2027. This short cash runway raises concerns about the company's near-term financial stability and its capacity to execute its business plans without additional capital, which can deter investors.
4. Underlying Weak Financial Performance.
Although the fiscal Q2 2026 earnings report, released on August 12, 2026, highlighted a decrease in general and administrative expenses and reported product revenue of $336,000 from fire safety equipment sales, the overall financial outlook, including a continued net loss from discontinued biopharmaceutical operations and the aforementioned limited cash runway, did not present a strong enough positive catalyst to offset the dilutive impacts of the pending merger and ongoing shareholder concerns.
Show less
Stock Movement Drivers
Fundamental Drivers
The -3.3% change in BGMS stock from 6/30/2026 to 10/4/2026 was primarily driven by a -18.7% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.91 | 0.88 | -3.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 22.0% |
| P/S Multiple | 3.3 | 2.6 | -18.7% |
| Shares Outstanding (Mil) | 5 | 6 | -2.5% |
| Cumulative Contribution | -3.3% |
Market Drivers
6/30/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| BGMS | -3.3% | |
| Market (SPY) | 3.1% | 7.9% |
| Sector (XLI) | -8.2% | 9.4% |
Fundamental Drivers
The -12.0% change in BGMS stock from 3/31/2026 to 10/4/2026 was primarily driven by a -63.4% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.00 | 0.88 | -12.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 149.1% |
| P/S Multiple | 7.2 | 2.6 | -63.4% |
| Shares Outstanding (Mil) | 5 | 6 | -3.5% |
| Cumulative Contribution | -12.0% |
Market Drivers
3/31/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| BGMS | -12.0% | |
| Market (SPY) | 18.6% | -3.3% |
| Sector (XLI) | 5.3% | -3.7% |
Fundamental Drivers
The -82.2% change in BGMS stock from 9/30/2025 to 10/4/2026 was primarily driven by a -99.6% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.94 | 0.88 | -82.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 2 | 18510.0% |
| P/S Multiple | 672.1 | 2.6 | -99.6% |
| Shares Outstanding (Mil) | 1 | 6 | -75.7% |
| Cumulative Contribution | -82.2% |
Market Drivers
9/30/2025 to 10/4/2026| Return | Correlation | |
|---|---|---|
| BGMS | -82.2% | |
| Market (SPY) | 16.5% | 12.4% |
| Sector (XLI) | 11.2% | 8.2% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2023 to 10/4/2026| Return | Correlation | |
|---|---|---|
| BGMS | ||
| Market (SPY) | 86.2% | 12.6% |
| Sector (XLI) | 74.3% | 8.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BGMS Return | - | - | - | - | -72% | -41% | -83% |
| Peers Return | 55% | -6% | 49% | 16% | 30% | 7% | 248% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| BGMS Win Rate | - | - | - | - | 0% | 33% | |
| Peers Win Rate | 63% | 50% | 60% | 53% | 53% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| BGMS Max Drawdown | - | - | - | - | - | -62% | |
| Peers Max Drawdown | -18% | -41% | -29% | -24% | -26% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WTS, WMS, UFPI, GFF, PPIH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/2/2026 (YTD)
How Low Can It Go
BGMS has limited trading history. Below is the Industrials sector ETF (XLI) in its place.
| Event | XLI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.8% | -18.8% |
| % Gain to Breakeven | 18.8% | 23.1% |
| Time to Breakeven | 34 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -11.7% | -9.5% |
| % Gain to Breakeven | 13.2% | 10.5% |
| Time to Breakeven | 45 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.1% | -24.5% |
| % Gain to Breakeven | 25.1% | 32.4% |
| Time to Breakeven | 125 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.6% | -33.7% |
| % Gain to Breakeven | 71.2% | 50.9% |
| Time to Breakeven | 231 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.7% | -19.2% |
| % Gain to Breakeven | 31.1% | 23.8% |
| Time to Breakeven | 120 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -11.1% | -12.2% |
| % Gain to Breakeven | 12.5% | 13.9% |
| Time to Breakeven | 51 days | 62 days |
In The Past
State Street Industrial Select Sector SPDR ETF's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
BGMS has limited trading history. Below is the Industrials sector ETF (XLI) in its place.
| Event | XLI | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.1% | -24.5% |
| % Gain to Breakeven | 25.1% | 32.4% |
| Time to Breakeven | 125 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.6% | -33.7% |
| % Gain to Breakeven | 71.2% | 50.9% |
| Time to Breakeven | 231 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.7% | -19.2% |
| % Gain to Breakeven | 31.1% | 23.8% |
| Time to Breakeven | 120 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -22.5% | -17.9% |
| % Gain to Breakeven | 29.0% | 21.8% |
| Time to Breakeven | 114 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -60.5% | -53.4% |
| % Gain to Breakeven | 153.2% | 114.4% |
| Time to Breakeven | 700 days | 1085 days |
In The Past
State Street Industrial Select Sector SPDR ETF's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bio Green Med Solution (BGMS)
Bio Green Med Solution (BGMS), operating as Cyclacel Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of cancer and other proliferative diseases. The company is dedicated to addressing significant unmet medical needs by advancing a pipeline of drug candidates designed to target the underlying mechanisms of these complex conditions. Through its research and development efforts, BGMS aims to improve patient outcomes in challenging disease areas.
The company's core business revolves around its proprietary development programs, each featuring a distinct therapeutic candidate in clinical trials. Key programs include fadraciclib, a cyclin dependent kinase (CDK) inhibitor in Phase 1/2 for solid tumors and chronic lymphocytic leukemia; CYC140, a polo-like kinase inhibitor also in Phase 1/2 for advanced leukemias and solid tumors; and Sapacitabine, a novel nucleoside analog undergoing Phase 1/2 trials for acute myeloid leukemia and myelodysplastic syndrome. Additionally, BGMS is developing seliciclib, another CDK inhibitor, which is being evaluated in investigator-sponsored trials for Cushing's disease and advanced rheumatoid arthritis, demonstrating a diversified approach to drug development.
Bio Green Med Solution primarily serves patients suffering from a range of severe conditions, including various hematological malignancies such as chronic lymphocytic leukemia, acute myeloid leukemia, and myelodysplastic syndromes, as well as those with solid tumors. Beyond oncology, the company's therapies target patients with Cushing's disease and advanced rheumatoid arthritis. BGMS strategically partners with leading institutions, such as the University of Texas MD Anderson Cancer Center, to conduct clinical evaluations, reinforcing its commitment to bringing innovative and effective treatment options to patients globally.
AI Analysis | Feedback
A small, early-stage Merck, but purely focused on developing new cancer drugs that are still in clinical trials.
Like a startup biotech aiming to discover the next breakthrough cancer treatment, similar to an early-stage Gilead Sciences.
Moderna, but for oncology drugs that are currently in clinical development, rather than vaccines.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer
Datuk Dr. Doris Wong Sing Ee was elected as the Chief Executive Officer and Executive Director of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025 after acquiring a controlling 70% stake in the company. She brings over 20 years of experience in various industries. Since October 2020, she has served as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been responsible for optimizing financial operations, establishing business goals, advising the board of directors on organizational activities, and executing special business projects. Dr. Wong has also been involved in various investment opportunities focused on business diversification, revenue generation, and increasing shareholders' wealth. Prior to her appointment at Cyclacel, she served as an independent director and a member of the audit and compensation committees of Energem Corp from November 2021 until January 2023.
Kiu Cu Seng, Chief Financial Officer
Kiu Cu Seng was appointed as Executive Director, Secretary, and Chief Financial Officer of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025. He brings significant accounting and audit experience to the company.
AI Analysis | Feedback
- Clinical Trial and Regulatory Approval Risk: The most significant risk for Bio Green Med Solution, based on the description, is the inherent uncertainty and high failure rate associated with clinical trials and the subsequent regulatory approval process for new drug candidates. The company's development programs, including fadraciclib, CYC140, Sapacitabine, and seliciclib, are all in Phase 1/2 clinical trials or investigator-sponsored trials. There is no guarantee that these drug candidates will demonstrate sufficient efficacy or safety in later-stage trials, or that they will ultimately receive the necessary regulatory approvals from health authorities like the FDA to be commercialized. Failure at any stage of development or inability to obtain approval would severely impact the company's prospects.
- Product Pipeline and Development Stage Risk: As a clinical-stage biopharmaceutical company, Bio Green Med Solution, as described, does not currently have any approved commercial products. Its future success and ability to generate revenue are entirely dependent on the successful development, approval, and commercialization of its pipeline candidates. If none of these candidates reach the market, the company would lack a sustainable revenue stream.
- Funding and Capital Needs: The research and development of pharmaceutical products, especially through extensive clinical trials, are highly capital-intensive processes. Bio Green Med Solution, as described, requires substantial ongoing funding to advance its various drug development programs. There is a risk that the company may not be able to secure adequate additional financing on favorable terms, or at all, which could lead to delays, curtailment, or even discontinuation of critical research and development efforts.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Capital Allocation Decisions (Bio Green Med Solution, Inc. - BGMS)
Share Issuance
- Bio Green Med Solution, Inc. implemented a 1-for-15 reverse stock split on its common stock, effective July 7, 2025, to meet Nasdaq bid price requirements. This action reduced the number of outstanding common shares from 23,759,475 to 1,583,965.
- The company executed other reverse stock splits, including a 1-for-15 split on December 18, 2023, and a 1-for-16 split on May 12, 2025.
- Bio Green Med Solution entered into multiple Warrant Exchange Agreements where existing warrants to purchase common stock were exchanged for newly issued common shares.
Inbound Investments
- Around late 2024/early 2025, there was an investment of $3.1 million in Preferred Stock, concurrently with the appointment of an Interim CEO.
Outbound Investments
- In September 2025, Bio Green Med Solution, Inc. completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based company specializing in fire safety and protection solutions, diversifying its business portfolio. As part of this Exchange Transaction, BGMS issued 699,158 shares of its common stock, representing 19.99% of its then-issued and outstanding common stock, in exchange for all of Fitters' equity interests.
- On October 6, 2025, the company acquired Assets and Rights of Plogosertib from Tethra Biosciences Inc. for $0.47 million.
Capital Expenditures
- Bio Green Med Solution Inc reported $0 in capital expenditures for Q3 2024.
- The company also reported $0 in capital expenditures for several quarters, including June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.
Peer Outperformance in Building Products
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Construction & Engineering | 31 | 9.9% | 133.1% | 195.8% | CDNL 2264% · STRL 2206% · FIX 2205% |
| Marine Transportation | 5 | 88.0% | 70.6% | 178.4% | HOS 39847% · MATX 195% · KEX 178% |
| Construction Machinery & Heavy Transportation Equipment | 13 | 3.5% | 54.9% | 103.6% | CAT 379% · ALSN 253% · WAB 231% |
| Aerospace & Defense | 54 | -12.8% | 64.8% | 71.1% | ATI 1031% · FTAI 826% · HWM 631% |
| Trading Companies & Distributors | 19 | 5.0% | 37.3% | 52.1% | DXPE 518% · AIT 284% · WCC 224% |
| Industrial Machinery & Supplies & Components | 72 | 14.5% | 52.3% | 50.2% | CRS 1129% · PSIX 1065% · EROC 627% |
| Rail Transportation | 7 | 20.0% | 62.7% | 48.3% | FSTR 138% · RAIL 64% · CSX 61% |
| Cargo Ground Transportation | 16 | 37.3% | 5.9% | 34.2% | XPO 287% · R 220% · CVLG 155% |
| Electrical Components & Equipment | 39 | 7.3% | 67.1% | 31.8% | POWL 2405% · BE 1469% · VRT 996% |
| Diversified Support Services | 33 | 9.3% | 33.6% | 30.2% | LIME 3065% · TH 369% · CXW 274% |
| Building Products ← | 33 | -14.9% | 3.0% | 17.7% | LMB 624% · GFF 356% · PPIH 269% |
| Industrial Conglomerates | 17 | 9.6% | 6.0% | -0.5% | RCMT 614% · CSW 133% · CSL 73% |
| Agricultural & Farm Machinery | 17 | 11.6% | 4.0% | -4.5% | BLBD 175% · DE 117% · GENC 59% |
| Environmental & Facilities Services | 30 | -18.6% | 21.1% | -8.2% | CECO 924% · ADUR 438% · NVRI 314% |
| Passenger Ground Transportation | 3 | -29.5% | 50.8% | -9.1% | UBER 49% · CAR -9% · LYFT -71% |
| Research & Consulting Services | 13 | -12.4% | -28.6% | -15.8% | HURN 221% · CRAI 72% · GRNQ 37% |
| Security & Alarm Services | 9 | -38.7% | 37.8% | -20.5% | CIX 156% · MG 110% · NL 70% |
| Office Services & Supplies | 9 | 13.5% | 18.9% | -28.5% | PBI 181% · TILE 123% · HNI 47% |
| Data Processing & Outsourced Services | 6 | -36.4% | -16.5% | -28.6% | EXLS 43% · BR 4% · G -25% |
| Passenger Airlines | 11 | 13.1% | 21.1% | -35.8% | LTM 2944% · UAL 121% · DAL 95% |
| Air Freight & Logistics | 12 | -32.1% | -21.8% | -37.2% | CHRW 103% · FDX 79% · EXPD 77% |
| Human Resource & Employment Services | 22 | 1.7% | -17.6% | -40.0% | BBSI 63% · ADP 41% · HQI 4% |
| Airport Services | 3 | -76.8% | -78.7% | -71.2% | JOBY -35% · ASLE -71% · UP -100% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can Bio Green Med Solution Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 85.59 |
| Mkt Cap | 4.2 |
| Rev LTM | 2,752 |
| Op Inc LTM | 461 |
| FCF LTM | 270 |
| FCF 3Y Avg | 324 |
| CFO LTM | 398 |
| CFO 3Y Avg | 365 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 17.1% |
| Rev Chg 3Y Avg | 3.3% |
| Rev Chg Q | 12.8% |
| QoQ Delta Rev Chg LTM | 4.7% |
| Op Inc Chg LTM | 7.4% |
| Op Inc Chg 3Y Avg | 15.1% |
| Op Mgn LTM | 16.7% |
| Op Mgn 3Y Avg | 17.0% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 11.4% |
| CFO/Rev 3Y Avg | 14.7% |
| FCF/Rev LTM | 9.8% |
| FCF/Rev 3Y Avg | 12.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Fire safety equipment | 1 | 0 | |||
| Safety aparel | 0 | 0 | |||
| Project - supply & installation | 0 | 0 | |||
| Maintenance & Servicing | 0 | 0 | |||
| Clinical trial supply | 0 | 0 | |||
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | 0 | 0 | 0 | ||
| Total | 1 | 0 | 0 | 0 | 0 |
| $ Mil | 2024 | 2023 |
|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | -12 | -25 |
| Total | -12 | -25 |
| $ Mil | 2024 | 2023 |
|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | -11 | -23 |
| Total | -11 | -23 |
| $ Mil | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | 28 | 43 | 37 | 15 | 26 |
| Total | 28 | 43 | 37 | 15 | 26 |
Price Behavior
| Market Price | $0.88 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/05/2004 | |
| Distance from 52W High | -85.2% | |
| 50 Days | 200 Days | |
| DMA Price | $3.73 | $4.58 |
| DMA Trend | down | up |
| Distance from DMA | -76.4% | -80.8% |
| 3M | 1YR | |
| Volatility | 69.7% | 122.0% |
| Downside Capture | 121.85 | 229.26 |
| Upside Capture | 4.66 | -6.31 |
| Correlation (SPY) | 11.9% | 12.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.22 | 1.08 | 0.66 | -0.30 | 1.18 | 0.15 |
| Up Beta | 1.76 | 2.78 | 1.99 | 2.00 | 3.67 | 1.15 |
| Down Beta | -0.15 | -1.21 | 1.21 | -6.19 | -0.77 | 0.47 |
| Up Capture | -39% | 69% | 6% | 26% | -9% | -1% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 9 | 19 | 28 | 56 | 104 | 108 |
| Down Capture | -79% | 94% | 28% | 90% | 156% | 92% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 13 | 23 | 36 | 65 | 139 | 145 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGMS | |
|---|---|---|---|---|
| BGMS | -82.3% | 121.7% | -0.85 | - |
| Sector ETF (XLI) | 11.5% | 17.3% | 0.46 | 8.2% |
| Equity (SPY) | 16.2% | 13.0% | 0.88 | 12.4% |
| Gold (GLD) | 6.8% | 29.6% | 0.22 | -0.2% |
| Commodities (DBC) | 44.9% | 20.8% | 1.67 | -6.0% |
| Real Estate (VNQ) | 1.5% | 13.6% | -0.15 | 5.7% |
| Bitcoin (BTCUSD) | -28.9% | 44.3% | -0.64 | 18.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGMS | |
|---|---|---|---|---|
| BGMS | -30.0% | 119.8% | -0.86 | - |
| Sector ETF (XLI) | 12.6% | 17.6% | 0.55 | 8.7% |
| Equity (SPY) | 13.1% | 17.2% | 0.58 | 12.6% |
| Gold (GLD) | 18.4% | 18.9% | 0.79 | 0.1% |
| Commodities (DBC) | 10.3% | 19.6% | 0.41 | -5.5% |
| Real Estate (VNQ) | 0.7% | 18.8% | -0.07 | 6.2% |
| Bitcoin (BTCUSD) | 14.6% | 52.2% | 0.45 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BGMS | |
|---|---|---|---|---|
| BGMS | -16.3% | 119.8% | -0.86 | - |
| Sector ETF (XLI) | 13.2% | 20.0% | 0.58 | 8.7% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 12.6% |
| Gold (GLD) | 11.5% | 16.4% | 0.57 | 0.1% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | -5.5% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 6.2% |
| Bitcoin (BTCUSD) | 64.1% | 66.2% | 1.04 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | -0.6% | -5.5% | 15.1% |
| 5/14/2026 | -5.1% | -6.1% | -20.5% |
| 11/13/2025 | -2.2% | -8.2% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 2 |
| # Negative | 3 | 3 | 1 |
| Median Positive | 7.5% | ||
| Median Negative | -2.2% | -6.1% | -20.5% |
| Max Positive | 15.1% | ||
| Max Negative | -5.1% | -8.2% | -20.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | -0.6% | -5.5% | 15.1% |
| 5/14/2026 | -5.1% | -6.1% | -20.5% |
| 11/13/2025 | -2.2% | -8.2% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 2 |
| # Negative | 3 | 3 | 1 |
| Median Positive | 7.5% | ||
| Median Negative | -2.2% | -6.1% | -20.5% |
| Max Positive | 15.1% | ||
| Max Negative | -5.1% | -8.2% | -20.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/02/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/29/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/02/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/29/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/12/2020 | 10-Q |
| 12/31/2019 | 03/05/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
Recent Forward Guidance
Updated 10/4/2026Latest: Q2 2026 Earnings Reported 8/14/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2027 Cash Resources | Reported | |||||||
Prior: Q1 2026 Earnings Reported 5/14/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Cash Runway | Reported | |||||||
Q3 2025 Earnings Reported 11/13/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Cash Runway | Reported | |||||||
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yap, Kim Choy | Direct | Sell | 11052025 | 1.70 | 28,540 | Form | |||
| 2 | Yap, Kim Choy | Direct | Sell | 11032025 | 1.81 | 112,260 | 202,854 | 51,500 | Form | |
| 3 | Kua, Khai Loon | Direct | Sell | 11032025 | 1.80 | 242,477 | Form | |||
| 4 | Ong, Yee Lung | Direct | Sell | 11032025 | 1.80 | 248,814 | Form | |||
| 5 | Yap, Kim Choy | Direct | Sell | 10312025 | 1.83 | 110,749 | 203,114 | 258,154 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yap, Kim Choy | Direct | Sell | 11052025 | 1.70 | 28,540 | Form | |||
| 2 | Yap, Kim Choy | Direct | Sell | 11032025 | 1.81 | 112,260 | 202,854 | 51,500 | Form | |
| 3 | Kua, Khai Loon | Direct | Sell | 11032025 | 1.80 | 242,477 | Form | |||
| 4 | Ong, Yee Lung | Direct | Sell | 11032025 | 1.80 | 248,814 | Form | |||
| 5 | Yap, Kim Choy | Direct | Sell | 10312025 | 1.83 | 110,749 | 203,114 | 258,154 | Form | |
| 6 | Yap, Kim Choy | Direct | Sell | 10302025 | 1.83 | 13,111 | 23,967 | 459,758 | Form | |
| 7 | Yap, Kim Choy | Direct | Sell | 10292025 | 2.12 | 120,250 | 254,690 | 560,465 | Form | |
| 8 | Ong, Yee Lung | Direct | Sell | 10282025 | 1.99 | 19,858 | 39,517 | 495,140 | Form | |
| 9 | Yap, Kim Choy | Direct | Sell | 10282025 | 1.90 | 19,595 | 37,270 | 732,023 | Form | |
| 10 | Fitters, Diversified Berhad | Direct | Sell | 10232025 | 3.00 | 92,352 | 277,518 | 839,140 | Form | |
| 11 | Fitters, Diversified Berhad | Direct | Sell | 10222025 | 3.09 | 108,107 | 333,834 | 1,147,501 | Form | |
| 12 | Kua, Khai Loon | Direct | Sell | 10202025 | 4.22 | 88,204 | 371,956 | 1,022,526 | Form | |
| 13 | Fitters, Diversified Berhad | Direct | Sell | 10202025 | 5.50 | 26,051 | 143,280 | 2,638,388 | Form | |
| 14 | Kua, Khai Loon | Direct | Sell | 10202025 | 5.66 | 7,479 | 42,339 | 1,871,985 | Form | |
| 15 | Ong, Yee Lung | Direct | Sell | 10162025 | 6.00 | 135,793 | 814,758 | 1,612,032 | Form | |
| 16 | Fitters, Diversified Berhad | Direct | Sell | 10142025 | 5.26 | 51,400 | 270,261 | 2,659,276 | Form | |
| 17 | Fitters, Diversified Berhad | Direct | Sell | 10102025 | 5.29 | 142,000 | 751,606 | 2,949,037 | Form | |
| 18 | Kua, Khai Loon | Direct | Sell | 10102025 | 5.13 | 25,000 | 128,300 | 1,735,437 | Form | |
| 19 | Kua, Khai Loon | Direct | Sell | 10102025 | 6.22 | 22,251 | 138,490 | 2,260,308 | Form | |
| 20 | Kua, Khai Loon | Direct | Sell | 9102025 | 7.01 | 19,054 | 133,569 | 2,701,731 | Form | |
| 21 | Lazar, David E | Direct | Sell | 8042025 | 12.36 | 6,750 | 83,430 | 1,926,158 | Form |
Industry Resources
| Industrials Resources |
| IndustryWeek |
| Manufacturing.net |
| Aviation Week |
| Building Products Resources |
| Building Design+Construction |
| Construction Dive |
| Architectural Record |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.